DrugPatentWatch Database Preview
Patent: 10,309,966
» See Plans and Pricing
Summary for Patent: 10,309,966
| Title: | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
| Abstract: | The present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, wherein the subject has been diagnosed or suspected of suffering from inflammation-associated cancer. These methods comprise determining the level of expression of EGFR in myeloid cells in a sample from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible to the treatment with an EGFR inhibitor/antagonist. |
| Inventor(s): | Sibilia; Maria (Vienna, AT) |
| Assignee: | Medizinische Universitat Wien (Vienna, AT) |
| Application Number: | 15/312,252 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,309,966
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 003 | 2006-09-27 | Start Trial | Medizinische Universitat Wien (Vienna, AT) | 2034-05-22 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 002 | 2006-09-27 | Start Trial | Medizinische Universitat Wien (Vienna, AT) | 2034-05-22 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Medizinische Universitat Wien (Vienna, AT) | 2034-05-22 | RX | search | |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Medizinische Universitat Wien (Vienna, AT) | 2034-05-22 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,309,966
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015177266 | Start Trial |
| United States of America | 2017184595 | Start Trial |
| European Patent Office | 2947460 | Start Trial |
| European Patent Office | 3146342 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
